Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMA Issues £70m Fines To Pfizer And Flynn Over Phenytoin

UK Regulator Finds Firms Abused Dominant Position To Overcharge NHS

Executive Summary

After reassessing part of a UK case involving Pfizer and Flynn Pharma over pricing for phenytoin sodium capsules, the country’s competition regulator has reaffirmed that the companies abused their dominant positions to overcharge the NHS and has issued £70m in fines.

You may also be interested in...



UK Court Declines To Back Phenytoin Fines

A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.

UK overturns £90m phenytoin price fines

Fines totalling almost £90 million (US$120 million) imposed on Pfizer and its marketing partner Flynn Pharma over allegedly unfair UK pricing for phenytoin sodium capsules have been overturned by the country’s Competition Appeal Tribunal. Having invited written submissions, the Tribunal intends to remit the dispute for reconsideration by the UK’s Competition and Markets Authority (CMA).

End Of Schultz Era Looms For Teva

Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel